Site search
2901 results for '' found
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients with Unresectable Locally
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients with Unresectable Locally
/
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in With Advanced Nonsmall Cell Lung Cancer who have Progressed
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in With Advanced Nonsmall Cell Lung Cancer who have Progressed
/
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEXX) (N
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEXX) (N
/
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophre
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophre
/
Secondary use of data study characterizing Kesimpta (ofatumumab) onboarding and utilization in RMS patients using MSGo, with a non-interventional primary use of data sub-study comparing Patient R
Secondary use of data study characterizing Kesimpta (ofatumumab) onboarding and utilization in RMS patients using MSGo, with a non-interventional primary use of data sub-study comparing Patient R
/
D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT): A Multi-Site, Randomised, Placebo-Controlled Trial (ACTRN12622001359729)
D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT): A Multi-Site, Randomised, Placebo-Controlled Trial (ACTRN12622001359729)
/
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Sub
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Sub
/
COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism (COBRRA) (NCT03266783)
COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism (COBRRA) (NCT03266783)
/